Leitlinie „Behandlung der Akne“ - AWMF
Leitlinie „Behandlung der Akne“ - AWMF
Leitlinie „Behandlung der Akne“ - AWMF
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
013/017 - Behandlung <strong>der</strong> Akne aktueller Stand: 02/2010<br />
korrigierte Fassung: 10/2011<br />
131. Niemeier V, Kupfer J, Demmelbauer-Ebner M, Stangier U, Effendy I, Gieler U.<br />
Coping with acne vulgaris. Evaluation of the chronic skin disor<strong>der</strong> questionnaire in<br />
patients with acne. Dermatology. 1998; 196: 108-15.<br />
132. Thiboutot D, Dreno B, Layton A. Acne counseling to improve adherence. Cutis. 2008;<br />
81: 81-6.<br />
133. Davies E, Patel C, Salek MS, Finlay AY. Does ad hoc quality-of-life discussion in<br />
inflammatory skin disease consultations reflect standardized patient-reported<br />
outcomes? Clin Exp Dermatol. 2008; 33: 16-21.<br />
134. Jones-Caballero M, Pedrosa E, Penas PF. Self-reported adherence to treatment and<br />
quality of life in mild to mo<strong>der</strong>ate acne. Dermatology. 2008; 217: 309-14.<br />
135. Pawin H, Beylot C, Chivot M, Faure M, Poli F, Revuz J, Dreno B. Creation of a tool<br />
to assess adherence to treatments for acne. Dermatology. 2009; 218: 26-32.<br />
136. Draelos ZK. Patient compliance: enhancing clinician abilities and strategies. J Am<br />
Acad Dermatol. 1995; 32: S42-8.<br />
137. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria<br />
clinically relevant? : implications of resistance for acne patients and prescribers. Am J<br />
Clin Dermatol. 2003; 4: 813-31.<br />
138. Fluhr JW, Gloor M, Dietz P, Hoffler U. In Vitro activity of 6 antimicrobials against<br />
propionibacteria isolates from untreated acne papulopustulosa. Zentralbl Bakteriol.<br />
1999; 289: 53-61.<br />
139. Ross JI, Eady EA, Cove JH, Ratyal AH, Cunliffe WJ. Resistance to erythromycin and<br />
clindamycin in cutaneous propionibacteria is associated with mutations in 23S rRNA.<br />
Dermatology. 1998; 196: 69-70.<br />
140. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, Tosti G,<br />
Katsambas A, Galvan Perez Del Pulgar JI, Rollman O, Torok L, Eady EA, Cove JH.<br />
Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003; 148: 467-78.<br />
141. Jones EL, Crumley AF. Topical erythromycin vs blank vehicle in a multiclinic acne<br />
study. Arch Dermatol. 1981; 117: 551-3.<br />
142. Perez Lopez M, Moragas Vinas JM. Nueva sal de eritromicina (A-137 o laurilsulfato<br />
de eritromicina) en el tratamiento topico del acne. Med Cutan Ibero Lat Am. 1982; 10:<br />
151-8.<br />
143. Prince RA, Busch DA, Hepler CD, Feldick HG. Clinical trial of topical erythromycin<br />
in inflammatory acne. Drug Intell Clin Pharm. 1981; 15: 372-6.<br />
144. Christian GL, Krueger GG. Clindamycin vs placebo as adjunctive therapy in<br />
mo<strong>der</strong>ately severe acne. Arch Dermatol. 1975; 111: 997-1000.<br />
145. Leyden JJ, Berger RS, Dunlap FE, Ellis CN, Connolly MA, Levy SF. Comparison of<br />
the efficacy and safety of a combination topical gel formulation of benzoyl peroxide<br />
and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments<br />
of acne vulgaris. Am J Clin Dermatol. 2001; 2: 33-9.<br />
146. Kurokawa I, Akamatsu H, Nishijima S, Asada Y, Kawabata S. Clinical and<br />
bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group<br />
comparison study versus cream base. J Am Acad Dermatol. 1991; 25: 674-81.<br />
Seite 114 von 136